Nanjing Delova Company Profile
What is the competitive landscape for NANJING DELOVA
NANJING DELOVA has one approved drug.
There is one US patent protecting NANJING DELOVA drugs.
Summary for Nanjing Delova
| US Patents: | 1 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Nanjing Delova
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nanjing Delova | QAMZOVA | meloxicam | SOLUTION;INTRAVENOUS | 217593-001 | Apr 22, 2025 | RX | Yes | Yes | 12,059,423 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Nanjing Delova Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 110464846 | ⤷ Start Trial |
| Japan | 2021521212 | ⤷ Start Trial |
| European Patent Office | 3777862 | ⤷ Start Trial |
| China | 116327959 | ⤷ Start Trial |
| China | 116327960 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2019214715 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
